Equities research analysts expect Vaccinex Inc (NASDAQ:VCNX) to post earnings of ($0.68) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Vaccinex’s earnings. The firm is expected to announce its next earnings report on Wednesday, June 12th.
On average, analysts expect that Vaccinex will report full-year earnings of ($2.20) per share for the current fiscal year, with EPS estimates ranging from ($2.29) to ($2.11). For the next year, analysts forecast that the business will post earnings of ($1.91) per share, with EPS estimates ranging from ($2.08) to ($1.73). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Vaccinex.
A number of research analysts have recently weighed in on the company. Oppenheimer set a $22.00 price objective on Vaccinex and gave the company a “buy” rating in a report on Wednesday, January 16th. ValuEngine lowered Vaccinex from a “buy” rating to a “hold” rating in a report on Friday, January 4th. Finally, Zacks Investment Research raised Vaccinex from a “sell” rating to a “hold” rating in a report on Saturday, January 5th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $22.00.
Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc acquired a new position in shares of Vaccinex in the third quarter valued at about $341,000. Vanguard Group Inc. acquired a new position in shares of Vaccinex in the third quarter valued at about $341,000. Bank of New York Mellon Corp acquired a new position in shares of Vaccinex in the third quarter valued at about $124,000. Finally, Telemetry Investments L.L.C. increased its holdings in shares of Vaccinex by 26.3% in the fourth quarter. Telemetry Investments L.L.C. now owns 14,720 shares of the company’s stock valued at $54,000 after purchasing an additional 3,066 shares during the period. 2.10% of the stock is currently owned by institutional investors and hedge funds.
Vaccinex Company Profile
Vaccinex, Inc is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Te firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington’s disease.
Featured Story: How is diluted EPS different from basic EPS?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.